Ingelheim Vetmedica, Inc, St. Joseph, Missouri]) were classified as Stage D heart failure.
Even in human medicine, a clear and precise definition of Stage D or advanced heart failure, has proven difficult. 2 In humans, Stage D heart failure has been described by some as "advanced progression and/or persistent severe signs and clinical signs of heart failure despite optimal medical, surgical, and device therapy." 3 Frequent hospitalization, severe exercise intolerance, and poor quality of life are key features of the syndrome.
Advanced heart failure in dogs represents a clinical challenge for veterinarians, not only with the precise definition, but optimal treatment since there are no studies or clinical trials that report clinical features and outcome for this population or are designed to evaluate treatment of dogs in this stage of disease. Therefore, the objective of our study was to describe the clinical findings and outcome of dogs with advanced heart failure secondary to DMVD.
| M A TE RI A L S A ND M E TH ODS
Dogs were eligible for inclusion in this retrospective study if they had been evaluated by the Cardiology Service at the Cummings Veterinary
Medical Center at Tufts University between January 2010 and February 2016, were diagnosed with DMVD, and had advanced heart failure.
The cardiology database and hospital electronic medical records were searched for dogs diagnosed with Stage D disease secondary to DMVD. Dogs classified with Stage C heart failure secondary to DMVD but that, after review of their medical history and records, met the study's definition of advanced heart failure were also included.
For the purposes of the study, advanced heart failure was defined as the recurrence of congestive heart failure signs despite a daily dose of furosemide >4 mg/kg/day, a recommended dose of pimobendan (0.5-0.6 mg/kg/day), and a maximally tolerated dose of ACEI. Dogs receiving a total daily dose of furosemide 4 mg/kg/day while receiving pimobendan and an ACEI with recurrent signs of congestive heart failure were included only if the total daily dose of furosemide was increased to >4 mg/kg/day, and if either at least 1 additional cardiac medication was introduced or if the dose of pimobendan was increased to an off-label dose. Prescription of other cardiac medications such as spironolactone, amlodipine, torsemide, or sildenafil before the date of the first recurrent episode of heart failure was permitted although dogs were classified in advanced heart failure only once they had recurrent congestive heart failure despite having been on these medications in addition to the previously described combination of furosemide (>4 mg/kg/day), pimobendan, and ACEI (ie, dogs that were receiving these other medications but were not receiving >4 mg/kg/day of furosemide were not enrolled). Dogs in Stage A or B and dogs that had
Stage C heart failure but died or were euthanized before meeting the criteria for advanced heart failure also were not enrolled. We purposely avoided the term, "Stage D heart failure" because our criteria for these dogs with severe, advanced heart failure deviates from the ACVIM Consensus Statement because it is our general practice to add in other cardiac medications before the furosemide dose reaches 6 mg/kg q12h. As a result of our deviation from the ACVIM Consensus definition of Stage D heart failure, we felt that avoiding the term "Stage D heart failure" and using a more general term of "advanced heart failure"
would be more accurate. were still alive at the end of the study (ie, the time of analysis) or were lost to follow up were right-censored.
| Statistical analysis
Data distributions were examined graphically and using Shapiro-Wilks tests to determine whether they were normally distributed or skewed.
Normal data are presented as mean 6 standard deviation and skewed data are presented as median (range). Kaplan-Meier survival curves and log-rank tests were used to evaluate survival times by dividing variables (eg, furosemide dose) into those less than or those greater or equal to the median. All statistical tests were performed with commercial statistical software (Systat 13.0, Systat, Inc, San Jose, California), and P values < .05 were considered statistically significant. 
| R E SU LTS

| Diagnosis of stage C heart failure
At the time of diagnosis of stage C heart failure, the mean age was 10.4 6 1.9 years. Median body weight was 6.5 kg (range, 3.1-65.9 kg) and median body condition score was 7 (range, 3-8; Table 1 ). Muscle condition (n 5 24) was scored as normal (n 5 11), mild muscle loss (n 5 11), or moderate muscle loss (n 5 2; Table 1 
| Diagnosis of advanced heart failure
All 54 dogs had successful resolution of initial Stage C congestive heart failure. The median time during which dogs were in stage C before advancing to advanced heart failure was 163 days (range, 10-743 days). At the time of diagnosis of advanced heart failure, dogs' mean age was 10.9 6 1.9 years. Median body weight was 6.7 kg (range, 2.4-68.3 kg) and median body condition score was 5 (range, 2-8; Table 1 ).
Muscle condition for the 36 dogs for which this information was available was categorized as normal (n 5 13; 36%), mild muscle loss (n 5 18; 50%), and moderate muscle loss (n 5 5; 14%), with no dogs having severe muscle loss. No muscle condition score recorded for 18 dogs (33%; Table 1 ). Eighteen dogs (33%) were hospitalized on the day of the diagnosis of advanced heart failure, with a median hospitalization duration of 1 day (range, 1-5 days).
The cardiac rhythms at the time of diagnosis of advanced heart fail- At the time of diagnosis of advanced heart failure, all 54 dogs were already receiving furosemide, pimobendan, and an ACEI ( Table 2) . A variety of other medications also were being administered. Eight dogs were receiving a dose of furosemide <4 mg/kg/day but, according to the predefined eligibility criteria, were included because all had their total daily dose of furosemide was increased to >4 mg/kg/day and either at least 1 additional cardiac medication was introduced (n 5 7
[spironolactone, n 5 6; amlodipine, n 5 1]) or the dose of pimobendan was increased to an off-label dose (n 5 4). Three dogs had both a medication addition and an increase in the pimobendan dose. A number of medication adjustments were made at the time of diagnosis of advanced heart failure. The dosages were increased for pimobendan (to above the recommended label dose; n 5 30), furosemide (n 5 28), ACEI (n 5 13), and spironolactone (n 5 4). New medications were also added to the medical regimen of many dogs: spironolactone (n 5 27), sildenafil (n 5 13), torsemide (n 5 5), and aldactazide/spironolactone (n 5 5), with some dogs having multiple medications added. The number of medications added varied: 1 medication added (n 5 33), 2 medications added (n 5 6), 3 medications added (n 5 1), and 4 medications added (n 5 1; Table 2 ). Overall, medication doses were adjusted in 46 Data are presented as number (for muscle condition score) or median (range) for muscle condition score category, the denominator indicates the number of dogs for which this information was available in the medical record, and the number in parentheses indicates the percentage.
dogs (85%) at the time of diagnosis of advanced heart failure and medications were added to the regimen in 41 dogs (76%).
| After the diagnosis of advanced heart failure
Forty-one of the 54 dogs (76%) were re-evaluated at our hospital after the diagnosis of AHF. The median number of re-evaluations after diagnosis of advanced heart failure was 1 (range, 0 -30). A median of 2 medication adjustments (range, 0-27) were made after the diagnosis of advanced heart failure. These included changes in furosemide Eighteen dogs required hospitalization during the time period after the diagnosis of advanced heart failure, with 2 dogs hospitalized twice.
After the diagnosis of advanced heart failure, most dogs lost body weight (n 5 30) but some gained weight (n 5 7 
| Survival analysis
At the time of analysis, 37 dogs had died and 17 were still alive; no dogs were lost to follow-up. Reasons for death included euthanasia for worsening heart failure or heart failure that did not respond to changes in medications (n 5 20, 54%), sudden death (n 5 14, 38%), and euthana- 
| D ISC USSION
Survival time after the diagnosis of advanced heart failure in this population of dogs with DMVD was longer than we anticipated based on our experience and clinical impression. Degenerative mitral valve disease is a progressive disease with a slow onset of clinical signs, and Advanced heart failure was defined as the persistence of congestive heart failure despite a daily dose of furosemide >4 mg/kg/day, a recommended dose of pimobendan (0.5-0.6 mg/kg/day), and a maximally tolerated dose of ACEI. Dogs receiving a total daily dose of furosemide 4 mg/kg/day while receiving pimobendan and an ACEI with recurrent signs of congestive heart failure were included only if the total daily dose of furosemide was increased to >4 mg/kg/day, and if either at least 1 additional cardiac medication was introduced or if the dose of pimobendan was increased to an offlabel dose. Data are presented as median (range).
many of the affected animals might die of an unrelated diseases. 6 However, once congestive heart failure develops, survival time is expected to be between 6 and 14 months. [7] [8] [9] In our study, the median duration between the diagnosis of stage C and advanced heart failure was 163 days, and the median survival time after the diagnosis of advanced heart failure was 281 days (9 months), with a range of 3-885 days.
While the majority of dogs died or were euthanized because of worsening heart failure, multiple factors other than the underlying cardiac disease can impact survival time in veterinary medicine, including medication adherence, financial issues, and owner preferences. Nonetheless, these findings could assist clinicians during communications regarding prognosis with owners of dogs with advanced heart failure because of DMVD.
In our study, one variable that was significantly associated with survival time was the furosemide dose after the diagnosis of advanced heart failure: a higher furosemide dose was significantly associated with longer survival time. This association has not been previously reported in the veterinary literature, although there are no previous publications describing the clinical course of dogs with advanced heart failure because of DMVD. In human patients with advanced heart failure, several studies have reported a negative association between a higher dose of loop diuretics and survival. [10] [11] [12] In addition to being in a different species, other study design differences make direct comparison with this study difficult. For example, some human studies used dose at discharge from hospitalization for advanced heart failure, 13 dose prescribed at the first ambulatory visit for heart failure, 12 or baseline dose from clinic visits for advanced heart failure. 10 This association, however, could be related more to disease severity, than to the diuretic dose. 11 In fact, a recent article assessed the ongoing dose of furosemide over 5 years in people with chronic heart failure and found that high doses of furosemide were not associated with worse survival when adjusted for patient characteristics and disease severity. 14 The second variable associated with survival time in our study was hospitalization at the time of diagnosis of advanced heart failure. While only 33% of dogs were hospitalized at the time of diagnosis of advanced heart failure, this was associated with a shorter survival time compared to dogs that were treated as outpatients. This could suggest that dogs requiring hospitalization for advanced heart failure have more severe or advanced disease. However, other possibilities such as owners' financial limitations or perception of poor prognosis also could have impacted owners' decisions of euthanasia and survival time. 15 Since there are no currently agreed upon indicators of severity of disease in dogs with advanced heart failure, we were not able to test this hypothesis in our study but this could be useful to investigate in future studies.
At the time of diagnosis of advanced heart failure, dogs were already receiving numerous medications, with some dogs receiving high doses. The variability in doses was related to disease severity and clinical signs, as well as the wide range in number and types of medications each dog was receiving. For example, some dogs received lower doses of furosemide because they were receiving multiple diuretics (eg, furosemide and spironolactone or furosemide and torsemide). The median dose of pimobendan at the time of diagnosis of advanced heart failure was 0.57 mg/kg/day, which is higher than the labeled-approved dose (0.5 mg/kg/day) but still within the recommended range given by the ACVIM Consensus Statement (0.5-0.6 mg/kg/day). However, some dogs were getting higher doses. These were typically dogs that were given pimobendan q8h at the time of their first onset of congestive heart failure (Stage C), and this dosing regimen was continued. This accounts for the high end of the dosage range shown in Table 2 . In addition, medications were used that did not reach consensus in the ACVIM Consensus Statement (eg, hydrochlorothiazide, sildenafil, torsemide).
Additional medication adjustments were made during the course of treatment after the diagnosis of advanced heart failure. This included increases or decreases in the medication dose, addition of medications, and, in some cases, discontinuation of medications. For example, the ACEI dose was decreased in 6 dogs and in 2 of these dogs, the ACEI was discontinued because of worsening azotemia. The majority of dogs (70%) were receiving at least 5 cardiac medications, with some dogs receiving up to 10 medications. These results are similar to those from human patients with heart failure in which polypharmacy (>5 medications) is common. 16 In one study of human patients with advanced heart failure that died during hospitalization, patients were taking a mean of 8.6 6 2.9 medications at the time of admission and 94% were receiving at least 5 medications.
17
Multiple medications were required to manage these dogs with advanced heart failure, but taking multiple medications also can increase the risk for adverse effects or drug interactions. At the time of diagnosis of advanced heart failure, multiple laboratory abnormalities were present, including hypochloremia, hyponatremia, polycythemia, and azotemia. Hypo-and hyperkalemia were uncommon, at the time of diagnosis of advanced heart failure, with only 2 and 1 dogs affected, respectively. Since this was a retrospective study, there were not predetermined time points for measurement of laboratory values, but after the diagnosis of advanced heart failure, laboratory abnormalities became even more common, with 81% of dogs having an increased BUN and 76% of dogs with hypochloremia at some point during treatment. Hypokalemia (37%) was less common and no dogs were identified to have hyperkalemia. It is unclear whether the azotemia was prerenal secondary to diuretic therapy, because of worsening heart disease and reduced cardiac output, or the result of primary renal disease.
Body weight and body composition changes also were common in this population of dogs with advanced heart failure. At all timepoints, dogs had a wide range of body condition scores, with most (even at late stages) having a body condition score 4/9, which is considered normal, and some being overweight or obese. Cachexia, which is a loss of muscle loss associated with disease, was very common and increased in prevalence from 54% at the time of diagnosis of Stage C heart failure to 64% at the time of diagnosis of advanced heart failure to 69% after the diagnosis of advanced heart failure. Cardiac cachexia is associated with reduced strength, impaired immune function, and, in people, increased mortality. 18, 19 The deleterious effects of cachexia support recommendations to assess muscle condition score, in addition to body condition score, in every patient at every visit, 5 since dogs can have cachexia despite a normal or overweight body condition score.
The prevalence of cachexia is similar to a previous study in dogs with heart failure secondary to dilated cardiomyopathy in which 54% of dogs were identified to have cachexia. 20 In our study, muscle condition scores were not available for all dogs, but this information now is included in the standard cardiovascular evaluation for all dogs in our hospital.
Our study has a number of important limitations that must be con- Although not all cardiologists will agree on our definition, we hope that these results from dogs with advanced heart failure provide a first step towards optimizing treatment for this population.
Another limitation is the retrospective nature of our study, so not all information was available for all dogs at the same timepoints. As previously mentioned, the option for euthanasia in veterinary medicine can impact survival time. In addition, owners of dogs with advanced heart failure who do not elect euthanasia at the time of advanced heart failure diagnosis are typically dedicated and might have more financial resources for medications and serial re-evaluations, which could influence survival time. The relatively small number of cases also limited the statistical power to find other potential associations with survival.
Finally, an important limitation is that these results are from a single institution and might reflect practice patterns and a population of dogs unique to this hospital. Therefore, they might not be representative of the general population of dogs with advanced heart failure since the treatment of these challenging cases can vary among different clinicians.
and important issues such as cost of care, quality of life, and individual owner preferences. Optimal treatment for dogs with advanced heart failure secondary to DMVD could not be determined from this retrospective study and has not yet reached consensus among veterinary cardiologists. Nevertheless, results from our study showed that dogs with advanced heart failure can have a relatively long survival time, with higher furosemide doses and non-hospitalization associated with longer survival.
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